Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and.
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
/PRNewswire/ As per Zion Market Research study, Radiopharmaceutical industry accrued ROI of approximately around US$ 5.8 billion in 2021 and is expected to.